Background: Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone. Materials and methods: In a randomized, double-blind controlled study conducted at 114 centers, we randomly assigned 5170 patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-totreat analysis. Treatment differences were assessed with the use of a Cox proportional-hazards model, with study center as a random effect. Result: Demographic data and clinical characteristics of the patients are presented in Table 1. There were 68 males and 22 females ranging in age from 34 to 78 years with the mean age of 61.71 ± 11.69 years. The most common subtypes of acute ischemic stroke as per TOAST criteria were as follows: large vessel, small vessel, and cardioembolic. Hypertension was most commonly observed risk factor for stroke. The other risk factors in decreasing order of frequency included CAD, diabetes, dyslipidemia, smoking, and alcohol. Conclusion: Ticagrelor plus ASA is expected to be effective for prevention of recurrence in mild non-cardioembolic stroke and high-risk TIA.